Drug Interactions between olanzapine / samidorphan and ritonavir
This report displays the potential drug interactions for the following 2 drugs:
- olanzapine/samidorphan
- ritonavir
Interactions between your drugs
ritonavir OLANZapine
Applies to: ritonavir and olanzapine / samidorphan
MONITOR: Coadministration with ritonavir may significantly decrease the plasma concentrations of olanzapine. The mechanism is ritonavir induction of CYP450 1A2 and uridine 5' diphosphate glucuronosyltransferase, the enzymes responsible for the metabolic clearance of olanzapine. In 14 healthy, nonsmoking volunteers, ritonavir (300 mg titrated to 500 mg orally twice a day over 11 days) decreased the mean peak plasma concentration (Cmax), area under the concentration-time curve (AUC) and half-life of olanzapine (10 mg single oral dose) by 40%, 53% and 50%, respectively, compared to administration of olanzapine alone. Oral clearance increased by 115%. All but one subject reported less sedation with olanzapine after ritonavir administration than before.
MANAGEMENT: Patients treated concomitantly with ritonavir may require a higher dosage of olanzapine to control psychotic symptoms. Pharmacologic response to olanzapine should be monitored more closely whenever ritonavir is added to or withdrawn from therapy in patients stabilized on their antipsychotic regimen, and the olanzapine dosage adjusted as necessary.
References (2)
- (2001) "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical
- Penzak SR, Hon YY, Lawhorn WD, Shirley KL, Spratlin V, Jann MW (2002) "Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers." J Clin Psychopharmacol, 22, p. 366-370
Drug and food interactions
ritonavir food
Applies to: ritonavir
ADJUST DOSING INTERVAL: Administration with food may modestly affect the bioavailability of ritonavir from the various available formulations. When the oral solution was given under nonfasting conditions, peak ritonavir concentrations decreased 23% and the extent of absorption decreased 7% relative to fasting conditions. Dilution of the oral solution (within one hour of dosing) with 240 mL of chocolate milk or a nutritional supplement (Advera or Ensure) did not significantly affect the extent and rate of ritonavir absorption. When a single 100 mg dose of the tablet was administered with a high-fat meal (907 kcal; 52% fat, 15% protein, 33% carbohydrates), approximately 20% decreases in mean peak concentration (Cmax) and systemic exposure (AUC) were observed relative to administration after fasting. Similar decreases in Cmax and AUC were reported when the tablet was administered with a moderate-fat meal. In contrast, the extent of absorption of ritonavir from the soft gelatin capsule formulation was 13% higher when administered with a meal (615 KCal; 14.5% fat, 9% protein, and 76% carbohydrate) relative to fasting.
MANAGEMENT: Ritonavir should be taken with meals to enhance gastrointestinal tolerability.
References (1)
- (2001) "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical
OLANZapine food
Applies to: olanzapine / samidorphan
GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
References (4)
- Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
- Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
- (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
- (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.